Clinical trials: Relapsed Pediatric AML, open to volunteers
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of…
- Trial name
- NCT06452732
- Testing
- MFC for the determination of leukemia stem cell
- Where
- 2 sites in China
- Volunteers
- 283 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancy, Leukemia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT06131801
- Testing
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed Pediatric AML, Refractory Pediatric AML
Vyxeos® With Clofarabine for Pediatric AML
Treatment with intensive chemotherapy in AML results in approximately 70% survival in newly diagnosed patients. Prognosis at relapse is worse and is in the 30-40% range.
- Trial name
- VyClo (NCT07156435)
- Testing
- Vyxeos 44 MG / 100 MG Liposome Injection, Clofarabine
- Where
- 13 sites in Austria, Denmark and 4 more
- Volunteers
- 25 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology